Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

RBM10 Mutation as a Potential Negative Prognostic/Predictive Biomarker to Therapy in Non-Small-Cell Lung Cancer.

Clinical lung cancer - 1 Dec 2024

Reyes Amanda, Afkhami Michelle, Massarelli Erminia, Fricke Jeremy, Mambetsariev Isa, Li Xiaochen, Velasquez Giovanny, Salgia Ravi

Abstract excerpt

BACKGROUND: According to WHO, lung cancer is the leading cause of cancer-related death worldwide, but treatment has advanced in the last decade. The widespread use of Next Generation Sequencing has led to the discovery of several pathogenic mutations including RNA binding motif 10 (RBM10), a part of the spliceosome complex that regulates splicing of pre-mRNA. PATIENTS AND METHODS: Electronic medical records were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Lung Neoplasms

Share to Mutation

Share to Prognosis

Share to RNA-Binding Proteins

Share to Survival Rate

Source

Open in PubMed Open full text

Identifiers

PMID: 39138107
DOI: 10.1016/j.cllc.2024.07.010
PMCID: PMC11588515

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

RBM10 Mutation as a Potential Negative Prognostic/Predictive Biomarker to Therapy in Non-Small-Cell Lung Cancer.PMID 39138107Read ↗

Frequent RBM10 Comutation and a Mutually Exclusive Relationship With Other TP53 Pathway Aberrations in Early-Stage Non-Small-Cell Lung Cancer with EGFR Mutation.Semantic proximity Read ↗

Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR-mutant lung cancerSemantic proximity Read ↗

Identification of non-actionable mutations with prognostic and predictive value in patients with advanced or metastatic non-small cell lung cancer.Semantic proximity Read ↗

Exploring the Cause of Survival Disparities in EGFR-mutated Lung Cancer Subtypes: Unraveling Distinctive Genomic and Phenotypic Features of 19Del and L858R Mutation SubtypesSemantic proximity Read ↗

RBM10 Loss Promotes EGFR-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition.Semantic proximity Read ↗

RNA binding motif protein 10 suppresses lung cancer progression by controlling alternative splicing of eukaryotic translation initiation factor 4H.Semantic proximity Read ↗

Clinical, Pathologic, and Molecular Prognostic Factors in Patients with Early-Stage EGFR-Mutant NSCLC.Semantic proximity Read ↗

The role of RBM10 mutations in the development, treatment, and prognosis of lung adenocarcinoma.Semantic proximity Read ↗

HRAS Q61L Mutation as a Possible Target for Non-Small Cell Lung Cancer: Case Series and Review of Literature.Semantic proximity Read ↗

Investigation of RBM10 mutation and its associations with clinical and molecular characteristics in EGFR-mutant and EGFR-wildtype lung adenocarcinomaSemantic proximity Read ↗

Functional analysis reveals that RBM10 mutations contribute to lung adenocarcinoma pathogenesis by deregulating splicing.Semantic proximity Read ↗

Real-world analysis of MET exon 14 mutations in non-small cell lung cancer: a retrospective study from two Swedish hospitals.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.